Common Reasons for Supplementary Submission Requests for Overseas Registration of Rehabilitation Devices

Key Summary

Common reasons for supplementary submission requests in overseas registration of rehabilitation devices mainly include: incorrect product classification, incomplete technical documentation, insufficient risk management and performance verification, inadequate clinical evaluation evidence, labeling and instructions for use not meeting target country requirements, mismatch between quality management system documentation and local regulations, improper appointment of local agent or authorized representative, and lack of post-market maintenance plans. Before preparing overseas registration dossiers, manufacturers should first confirm whether the product falls within the scope of medical device regulation in the target country, then determine the risk class and registration pathway, and assess whether existing documents such as NMPA, CE, FDA, ISO 13485, and MDSAP can be reused. For multi-country registration scenarios involving GHWP member states, Southeast Asia, the Middle East, or Latin America, manufacturers should establish a core technical documentation library and perform localized conversion according to each country's requirements to avoid repeated compilation and deficiency responses. Manufacturers must pay attention to the qualifications and responsibilities of local agents, ensure clarity regarding certificate control, changes, and renewal processes, and plan in advance for post-market surveillance, adverse event reporting, and vigilance systems. Supplementary submission is not simply a matter of providing missing documents—it requires a systematic re-evaluation of the product's safety and performance evidence chain.

Compiled based on the AIMEILI Registration Practice Question Bank, the Medical Device International Registration Knowledge Base, and publicly available regulatory information. For specific projects, always refer to the latest requirements of the target country's regulatory authority and the actual product documentation basis.

Common Follow-up Questions

Can deficiency requests appear repeatedly?

Yes. If the first deficiency response fails to fully address the reviewer's core concerns, a second round of requests may be issued. Common situations include submitting only test reports without updating the risk management report, or providing clinical evaluation that still fails to demonstrate that benefits outweigh risks. It is recommended to prepare a detailed difference table when responding to deficiency letters, specifying the modifications made and the rationale for each answer, so that reviewers do not consider the response incomplete.

Are deficiency mechanisms the same across different countries?

No. Some countries allow formal communication with regulatory authorities during the review process, while others only accept written responses. Certain GHWP member states adopt a single-round deficiency model, where failure to pass results in direct rejection. Manufacturers should proactively learn about the number of allowed deficiency rounds, timelines, fees, and response format requirements for each target country.

Can new evidence be submitted during the deficiency response phase?

Generally yes, and new evidence often helps resolve review questions. However, ensure that the new evidence is still valid at the time of submission and does not conflict with the original application file. If clinical data is needed, manufacturers should assess whether a new clinical trial or literature search can be completed within the limited timeframe. Conducting additional studies on a temporary basis may significantly extend the overall registration timeline.

What if the deficiency reason is not clear?

If the manufacturer is uncertain about the basis for the deficiency request, it is advisable to seek assistance from local regulatory consultants or professional CROs. Do not rely on experience from other markets, as deficiency letters cite specific regulatory clauses and reference guidelines that require professional interpretation.

Deficiency response documents should maintain language consistency, follow the numbering format required by the regulatory authority, and retain all correspondence records. These records are very important for future changes and renewals.

Applicable Scenarios and Core Issues

Companies searching for "common reasons for supplementary submission requests in overseas registration of rehabilitation devices" usually want to solve practical problems rather than get a conceptual explanation: whether existing documentation can support target market filings, whether a local agent or authorized representative is needed, why the timeline has been extended, and which issues will affect the launch plan. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

For manufacturers planning to enter multiple GHWP member states, Southeast Asia, the Middle East, or Latin America, answering the process of a single country is not sufficient. A more valuable approach is to first create reusable versions of core technical documents, quality system certificates, performance validation reports, clinical evidence, and labels, and then perform localization adjustments according to each country's regulatory requirements.

Registration Judgment Logic

Manufacturers should first confirm the product's intended use, mechanism of action, use scenario, mode of contact with the human body, duration of use, whether it is sterile, whether it is powered, whether it contains software or IVD attributes, and then determine the risk class and registration pathway. If the pathway is determined incorrectly, all subsequent translation, notarization, authorization, testing, and supplementary document activities will deviate from the direction.

For target market projects, it is also necessary to define the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are only vaguely handled in commercial contracts, market control may be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system certificate, technical documentation, performance verification reports, risk management files, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance data.

The quality of documentation is not determined by quantity, but by consistency. The claims in the instructions for use, test report coverage of models, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities are concerned with whether the product is safe, effective, and traceable under the intended use, not whether the manufacturer has uploaded many files.

Common Errors

The most common problem is treating the registration project as a simple document submission, without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating NMPA documents without restructuring the evidence according to the target market pathway.
• Excessive model and specification variations, but incomplete coverage in test reports, clinical evidence, or labeling.
• Selecting a local agent based only on sales cooperation, without defining regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistency among labels, instructions, promotional materials, and registration documents, leading to deficiency requests or post-market compliance risks.
• Lack of advance planning for document reuse across multiple countries, causing repeated compilation and increased cost and time.

Manufacturer Preparation Checklist

Before starting the project, manufacturers are advised to use an internal checklist to confirm the documentation baseline, so as to avoid discovering critical evidence gaps only after submission.

• Compile the target product list, model and specification matrix, and intended use description.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management documents, clinical evaluation, and English instructions for use.
• Confirm the responsibilities, fees, certificate control rights, and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table, identifying the need for additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI advises manufacturers not to understand target market registration as a one-time document submission, but to manage it as an overseas market access engineering project. For manufacturers planning to enter multiple countries, establishing a clear set of core technical documents and an evidence matrix first, and then converting according to national requirements, is usually faster and more reliable than preparing documents on a country-by-country basis, and is also more conducive to future changes and renewals.

From a project management perspective, manufacturers should control three things in advance: first, product classification and pathway judgment; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are not clear, even if the dossier seems large, the project may still face repeated deficiency responses, communication issues with agents, and post-market maintenance failures.

Project Implementation Recommendations

During project execution, manufacturers should establish a project ledger that manages the product list, model specifications, registration pathway, document responsible persons, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps to identify document gaps in a timely manner and allows management to judge whether the project will affect the launch plan.

For manufacturers with existing registration experience in multiple countries, an evidence reuse matrix should also be established to clarify which documents can be used as core evidence and which must be re-issued or supplemented according to national requirements. In particular, labels and instructions, clinical evaluation, risk management, performance verification, and quality system certificates should keep consistent versions.

• Confirm the target market and product list.
• Conduct risk classification and pathway judgment.
• Establish a document gap assessment table.
• Clarify local agent and certificate control responsibilities.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a regulatory review perspective, quality system documentation is not just an isolated certificate. Regulatory authorities usually check for consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical documentation. If the scope of the ISO 13485 certificate does not match the applied product, or if the production address, model specifications, or labeling version do not match the test report, deficiency requests may be issued even if the manufacturer has prepared a large number of files.

Manufacturers should create an evidence consistency checklist before submission, matching product name, model specifications, intended use, applicable standards, test report number, clinical evaluation conclusion, risk management version, labeling version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of deficiency requests, especially for projects involving multiple GHWP member states or multiple product lines simultaneously.

Localization and Agent Responsibilities

Target market registration projects usually involve the appointment of a local agent, authorized representative, importer, or registration holder. Manufacturers should confirm in advance whether the local partner is only responsible for submitting documents, or also assumes responsibility for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and market stability.

Labels and instructions for use, as well as authorization documents, cannot simply be translated. Manufacturers should verify local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For manufacturers that already have CE, FDA, NMPA, or other market documents, the key to localization is converting reusable evidence into an acceptable submission structure for the target country, rather than writing a completely new and isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Obtaining registration does not mean the end of compliance work. Manufacturers still need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many manufacturers invest significant effort during the registration phase but ignore post-market maintenance. Later, when a production address change, model expansion, labeling update, or agent replacement occurs, the certificate may become disconnected from market sales.

AIMEILI recommends incorporating this issue into the annual international registration plan. First, set target market priorities; second, establish a reusable document package and national gap list; and finally, arrange submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency for a single country, but more importantly, to enable the manufacturer to develop a replicable overseas compliance capability and reduce the cost of starting from scratch each time they enter a new market.

Further Reading

Previous: How is product classification determined for overseas registration of rehabilitation devices?

Next: What are the requirements for risk management documentation in overseas registration of rehabilitation devices?

Recommended Reading

• How to localize labels and instructions for overseas registration of rehabilitation devices?
• How is product classification determined for overseas registration of rehabilitation devices?
• What are the requirements for risk management documentation in overseas registration of rehabilitation devices?
• How to prepare clinical evaluation data for overseas registration of implantable products?
• How to prepare registration documents for overseas registration of implantable products?
• How to localize labels and instructions for overseas registration of implantable products?

Content Review and Applicability

Content author: AIMEILI Regulatory Editorial Department

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standard organizations, and public regulatory materials; industry media and project experience are used only as supplementary reference.

Applicability: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace formal requirements from target country regulatory authorities, testing conclusions, or legal advice.